A polypeptide that selectively degrades pd-l1 protein on tumor cell membrane and its application

A selective and biologically active technology, applied in the field of peptides and applications that selectively degrade PD-L1 protein on tumor cell membranes, to achieve high biocompatibility, inhibit growth speed, and restore immune killing effects
CN113072622BActive Publication Date: 2022-08-05NANKAI UNIV
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
NANKAI UNIV
Publication Date
2022-08-05

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the technical field of medicine and pharmacy, in particular to a polypeptide for selectively degrading PD-L1 protein on tumor cell membranes and its application. The polypeptide of the present invention can undergo enzymatic in situ self-assembly under the action of ALP overexpressed in tumor cells, and the polypeptide molecule has a molecule that can specifically bind to PD-L1. D The PPA-1 sequence enables the self-assembled polypeptide nanofibers to selectively bind to PD-L1 on the tumor cell membrane to simulate its partial denaturation state, and is then endocytosed into cells and degraded through the proteasome pathway, thereby effectively degrading The PD-L1 protein on the tumor cell membrane relieves the control of tumor cells on the immune system and provides new ideas for the preparation of tumor immunotherapy drugs.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of medicine and pharmacy, in particular to a polypeptide for selectively degrading PD-L1 protein on tumor cell membranes and its application. Background technique

[0002] Immunotherapy has become the fourth tumor treatment method after surgery, radiotherapy and chemotherapy. In particular, the treatment of immune checkpoint molecules has achieved very positive therapeutic effects in the clinical treatment of tumors. Among numerous immunotherapy-related studies, the T cell-based PD-1 (programmed death receptor 1) / PD-L1 (programmed death ligand 1) immune checkpoint pathway is considered to expand immunity The mainstay of therapy has gained enormous attention. Previous studies have shown that overexpression of PD-L1 in tumor cells enhances tumor viability and metastasis, leading to tumor immune escape. Tumor cells will undergo immunosuppression through the PD-1 / PD-L1 pathway to achieve local growth and compl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More